Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2016
Reporting Period: Third Quarter ended September 30, 2016
This filing serves to announce the Company's financial results for the quarter ended September 30, 2016, and provides a clinical update regarding its Duchenne muscular dystrophy (DMD) program.
Key Financial Metrics
The filing text references the issuance of a press release containing financial results but does not explicitly state specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached Exhibit 99.1 for detailed financial figures.
Material Changes and Clinical Updates
- Financial Results: The Company reported third-quarter 2016 financial results via a press release (Exhibit 99.1).
- Clinical Development: The Company announced plans to expand its clinical development program for Duchenne muscular dystrophy. The expansion aims to evaluate peripheral and respiratory muscle function (Exhibit 99.2).
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, quantitative outlooks, or detailed risk factors. It notes that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q3 2016 revenue, net loss, cash position, and operating expense details.
- Examine Exhibit 99.2 for the specific design and timeline of the expanded Duchenne muscular dystrophy clinical trial.
- Verify the Company's cash runway and burn rate based on the full financial statements referenced in the press release.
- Confirm any regulatory milestones associated with the new clinical evaluation of peripheral and respiratory muscle function.